文献速递角膜与眼表疾病

个性化角膜交联术治疗超薄角膜:Sub400方案

Individualized Corneal Cross-linking With Riboflavin and UV-A in Ultrathin Corneas: The Sub400 Protocol.
PubMed 文献 · Am J Ophthalmol · 2021-01-30

这项回顾性介入病例系列研究纳入39眼进展性圆锥角膜且角膜基质厚度214-398μm,采用个体化紫外照射(3 mW/cm²)的Sub400方案。最薄基质厚度、Kmax和密度值显著变化,而CDVA、球镜和柱镜无显著变化。

要点

  • Sub400方案在超薄角膜中12个月阻止圆锥角膜进展成功率达90%。
  • 治疗范围可扩展至角膜基质厚度仅214μm的眼。
  • 基质分界线深度与照射时间显著相关,但不预测治疗结果。

核心结论

  • Sub400个体化通量CXL方案可标准化治疗超薄角膜并在12个月以90%成功率阻止圆锥角膜进展。
  • 该方案允许治疗角膜基质薄至214μm的眼,显著扩展治疗范围。
  • 基质分界线深度不预测治疗结果,可能与CXL诱导的微观结构改变和伤口愈合有关而非角膜硬化程度。

研究设计与样本

  • 回顾性介入病例系列,纳入39眼进展性圆锥角膜且紫外照射时角膜基质厚度214-398μm。
  • 上皮去除后以3 mW/cm²进行紫外照射,照射时间根据基质厚度个体化调整。

主要发现

  • 分界线深度与照射时间显著相关(r=+0.448,P=.004),但与Kmax变化无显著相关(r=-0.215,P=.189)。
  • 最薄基质厚度平均变化-14.5±21.7μm、Kmax平均变化-2.06±3.66 D、密度值平均变化+2.00±2.07 GSU,均P<.05。
  • CDVA(P=.611)、球镜(P=.077)和柱镜(P=.915)无显著变化。

临床怎么用

  • 对进展性圆锥角膜且角膜基质极薄(低至214μm)的患者可考虑采用个体化通量的Sub400 CXL方案。
  • 术后评估应关注地形图稳定性和内皮功能,分界线深度不宜作为疗效预测指标。

局限性

  • 回顾性、非对照病例系列设计,样本量39眼,随访12个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether corneal cross-linking (CXL) with individualized fluence ("sub400 protocol") is able to stop keratoconus (KC) progression in ultrathin corneas with 12-month follow-up. DESIGN: Retrospective, interventional case series. METHODS: Thirty-nine eyes with progressive KC and corneal stromal thicknesses from 214 to 398 μm at the time of ultraviolet irradiation were enrolled. After epithelium removal, ultraviolet irradiation was performed at 3 mW/cm2 with irradiation times individually adapted to stromal thickness. Pre- and postoperative examinations included corrected distance visual acuity (CDVA), refraction, Scheimpflug, and anterior segment optical coherence tomography imaging up to 12 months after CXL. Outcome measures were arrest of KC progression at 12 months postoperatively and stromal demarcation line (DL) depth. RESULTS: Thirty-five eyes (90%) showed tomographical stability at 12 months after surgery. No eyes showed signs of endothelial decompensation. A significant correlation was found between DL depth and irradiation time (r = +0.448, P = .004) but not between DL depth and change in Kmax (r = -0.215, P = .189). On average, there was a significant change (P < .05) in thinnest stromal thickness (-14.5 ± 21.7 μm), Kmax (-2.06 ± 3.66 D) and densitometry (+2.00 ± 2.07 GSU). No significant changes were found in CDVA (P = .611), sphere (P = .077), or cylinder (P = .915). CONCLUSIONS: The "sub400" individualized fluence CXL protocol standardizes the treatment in ultrathin corneas and halted KC progression with a success rate of 90% at 12 months. The sub400 protocol allows for the treatment of corneas as thin as 214 μm of corneal stroma, markedly extending the treatment range. The DL depth did not predict treatment outcome. Hence, the depth is unlikely related to the extent of CXL-induced corneal stiffening but rather to the extent of CXL-induced microstructural changes and wound healing.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hafezi F, Kling S, Gilardoni F, et al. Individualized Corneal Cross-linking With Riboflavin and UV-A in Ultrathin Corneas: The Sub400 Protocol. Am J Ophthalmol. 2021. PMID: 33340508. doi:10.1016/j.ajo.2020.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。